Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice
Fructose intake from added sugars correlates with the epidemic rise in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Fructose intake also causes features of metabolic syndrome in laboratory animals and humans. The first enzyme in fructose metabolism is fructokinase, which exists...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 109; no. 11; pp. 4320 - 4325 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
13.03.2012
National Acad Sciences |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Fructose intake from added sugars correlates with the epidemic rise in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Fructose intake also causes features of metabolic syndrome in laboratory animals and humans. The first enzyme in fructose metabolism is fructokinase, which exists as two isoforms, A and C. Here we show that fructose-induced metabolic syndrome is prevented in mice lacking both isoforms but is exacerbated in mice lacking fructokinase A. Fructokinase C is expressed primarily in liver, intestine, and kidney and has high affinity for fructose, resulting in rapid metabolism and marked ATP depletion. In contrast, fructokinase A is widely distributed, has low affinity for fructose, and has less dramatic effects on ATP levels. By reducing the amount of fructose for metabolism in the liver, fructokinase A protects against fructokinase C-mediated metabolic syndrome. These studies provide insights into the mechanisms by which fructose causes obesity and metabolic syndrome. |
---|---|
Bibliography: | http://dx.doi.org/10.1073/pnas.1119908109 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by Kosaku Uyeda, University of Texas Southwestern Medical Center and Veterans Affairs Medical Center at Dallas, Dallas, TX, and accepted by the Editorial Board January 24, 2012 (received for review December 6, 2011) Author contributions: T.I. and R.J.J. designed research; T.I., M.A.L., M.T.L., and G.E.G. performed research; C.P.D., A.A., T.K., S.M., L.G.S.-L., and D.T.B. contributed new reagents/analytic tools; P.S.M., M.R.J., C.A.R.-J., C.J.R., and B.R.-I. analyzed data; and T.I., Y.Y.S., and R.J.J. wrote the paper. 1Present address: Division of Renal Diseases and Hypertension, University of Colorado Denver, Box C281, 12700 E 19th Ave., Research 2 Room P15-7006, Aurora, CO 80045. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1119908109 |